ChangeBridge: Patent Apps - Pharma (A61K)
Thursday, March 26, 2026
Patent Application for Whitening Cosmetic Composition with Artemisinic Acid
The USPTO has published a patent application (US20260083657A1) for a whitening cosmetic composition containing artemisinic acid, nicotinamide, and/or glutathione. The application, filed by Yunnan Botanee Bio-Technology Group Co., Ltd., describes a formulation designed to inhibit melanin production and reduce skin irritation.
Patent Application for Hyaluronic Acid Production Stimulation
The USPTO has published a new patent application (US20260083656A1) filed by Alastin Skincare, Inc. The application details compositions and methods for stimulating intrinsic hyaluronic acid production to improve skin moisture and elasticity. This is a routine publication of a patent application.
Patent Application: Compositions with Sophorolipids and Lactic Acid
The USPTO has published a new patent application (US20260083655A1) filed by Evonik Operations GmbH. The application describes compositions containing sophorolipids and lactic acid for cleaning or skin moisturizing. This is a routine filing for a new patent application.
Patent Application: Tumor Targeting Methods and Reagents
The USPTO has published a patent application (US20260083867A1) detailing methods and reagents for tumor targeting in cancer treatment. The application, filed on November 21, 2025, describes a combination therapeutic approach using agents with different biodistributions to enhance efficacy and reduce toxicity.
USPTO Patent Application for PSMA Ligands
The USPTO has published a new patent application (US20260083865A1) filed by 3B Pharmaceuticals GMBH for prostate specific membrane antigen (PSMA) ligands. The application details a compound of Formula (I) and its use in treating cancer.
USPTO Patent Application for Disease Treatment Method
The USPTO has published patent application US20260083666A1 for a method of treating diseases and ameliorating pain by administering a composition to the ear canal. The application was filed on April 10, 2025, and published on March 26, 2026.
Patent Application for Contrast Agents in Diagnostic Imaging
The USPTO has published a patent application (US20260083864A1) for a new class of compounds intended for use as contrast agents in diagnostic imaging, including computed tomography (CT) and magnetic resonance imaging (MRI). The application details specific compound formulas, metal chelates, and preparation methods.
Patent Application: Treating Brain Diseases with rAAV Particles
The USPTO has published a new patent application (US20260083862A1) from the University of Iowa Research Foundation detailing methods for treating brain diseases using rAAV particles administered via the cisterna magna. The application was filed on May 19, 2025.
CRISPR Methods Targeting CD70 Expression for Engineered Cells
The USPTO has published a patent application (US20260083861A1) filed by Editas Medicine, Inc. The application describes CRISPR-related systems and methods for targeting the CD70 gene expression in engineered cells, particularly T cells, for potential therapeutic applications.
Patent Application for Genome Editing Compositions and Methods
The USPTO has published a new patent application (US20260083860A1) for genome editing compositions and methods. The application, filed on August 19, 2025, by inventors Oscar ALVAREZ, Ming-Yue LEE, and Blair B. MADISON, details methods and compositions for functional genetic modifications.
Source details
Activity
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get ChangeBridge: Patent Apps - Pharma (A61K) alerts
We'll email you when ChangeBridge: Patent Apps - Pharma (A61K) publishes new changes.